biotech stocks

Inside Wall Street: Where M&A Could Heat Up in Biotech

M&A-watchers see a buyout happening soon in a secluded sector of biotech: DNA sequencing and genetic analysis. One potential buyer is big player Illumina, and one potential buyout target is Wafergen Bio-Systems, whose SmartChip technology is a game-changer.

Why Hot Biotech Dendreon Could Get Even Hotter

Dendreon is developing immunologically based drugs to fight cancer, and it's No. 1 drug is Provenge, which battles prostate cancer. The excitement is about whether Provenge finally gets the FDA's approval this year. If so, the stock could keep scoring.

2010 Could Be Big for Small Biotechs

Biotech stocks surprised in 2009 by surging. Equally surprising was the robust performance of the young and small-cap crowd of mostly development-stage companies, which trumped their large-cap brethren. That pattern could prevail again this year.

Amgen Misses Street's Expectations

Amgen, the world's largest biotechnology company, reported fourth-quarter results that missed Wall Street's expectations, as a 2% increase in sales failed to translate into a stronger bottom line.